1 unchanged sentence
Trading Plans
−Removed: During the three months ended March 31, 2026 , no director or officer (as defined in Rule 16a - 1 (f) under the Exchange Act) of the Company adopted or terminated a “Rule 10b5 - 1 trading arrangement” or “non-Rule 10b5 - 1 trading arrangement,” as each term is defined in Item 408 (a) of Regulation S-K.
+Added: During the three months ended June 30, 2026 , our directors (as defined in Rule 16a - 1 (f) under the Exchange Act) who adopted or terminated contracts, instructions, written plans or arrangements for the purchase or sale of our securities are set forth in the table below:
+Added: Trading Arrangement
+Added: Total Shares of Common
+Added: Name and Title
+Added: Rule 10b5 - 1*
+Added: Non-Rule 10b5 - 1**
+Added: Stock to be Sold
+Added: Expiration Date
+Added: Allison Dorval , Board Member
+Added: June 16, 2026
+Added: Up to 10,193 shares
+Added: Alessandra Cesano , Board Member
+Added: June 15, 2026
+Added: Up to 62,150 shares
+Added: December 31, 2026
+Added: Troy Wilson , Board Member
+Added: June 15, 2026
+Added: Up to 18,500 shares
+Added: June 17, 2027
+Added: Adrian Senderowicz , Board Member
+Added: June 16, 2026
+Added: Up to 27,000 shares
+Added: June 25, 2027
Exhibits required by Item 601 of Regulation S-K.
1 unchanged sentence
Fifth Amended and Restated Bylaws of the Company (filed as Exhibit 3.1 to the Company ’ s Current Report on Form 8-K filed with the SEC on June 24, 2025, and incorporated herein by reference)
−Removed: Ninth Amendment to Note Purchase Agreement and Firth Amendment to Disclosure Letter, dated April 16, 2026 by and between the Company and Athyrium Opportunities IV Co-Invest 1 LP, as Administrative Agent
−Removed: Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 with respect to the registrant ’ s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026
−Removed: Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant ’ s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026
+Added: Ninth Amendment to Note Purchase Agreement and Fifth Amendment to Disclosure Letter, dated April 16, 2026 by and between the Company and Athyrium Opportunities IV Co-Invest 1 LP, as Administrative Agent (filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 7, 2026, and incorporated herein by reference)
+Added: Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 with respect to the registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026
+Added: Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026
Certification of Principal Executive Officer pursuant to 18 U.S.C.
13 unchanged sentences
PUMA BIOTECHNOLOGY, INC.
+Added: August 6, 2026
President and Chief Executive Officer
(Principal Executive Officer)
+Added: August 6, 2026
/s/ Maximo F.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.